Khashayar Dashtipour

Dr. Khashayar Dashtipour, MD, PhD, serves as Professor of Neurology in the School of Medicine and Associate Professor of Pharmacy Practice in the School of Pharmacy at Loma Linda University. He also holds an Associate Professor position in the Basic Sciences Pharmacology Division within the School of Medicine. His academic career spans multiple disciplines at the intersection of neurology and pharmacology, with a focus on movement disorders and therapeutic interventions.

Dr. Dashtipour's research interests center on Parkinson's disease, movement disorders including dystonia and essential tremor, and the therapeutic applications of botulinum toxin. His work encompasses clinical trials, pharmacological interventions, and innovative treatment approaches for neurological conditions. He has made significant contributions to understanding the mechanisms and management of spasticity, sialorrhea, and other movement disorder symptoms.

Analysis of his recent publications reveals a strong focus on botulinum toxin therapies across multiple indications, with particular attention to dosing protocols, safety profiles, and comparative effectiveness. His research also extends to Parkinson's disease therapeutics, genetic factors in movement disorders, and health disparities in neurological care. The publication trend shows consistent output with increasing emphasis on precision medicine approaches and real-world evidence.

Dr. Dashtipour has served as Principal Investigator on numerous clinical trials, including NIH-funded studies and industry-sponsored research with major pharmaceutical companies. His current projects include investigations into DNA methylation patterns in Parkinson's disease, novel treatments for cervical dystonia, and studies examining the relationship between spirituality and Parkinson's disease outcomes.

His research program demonstrates a comprehensive approach to movement disorders, spanning basic science investigations, clinical trials, and translational research aimed at improving patient outcomes through evidence-based therapeutic interventions.